Arvinas (ARVN) Stock Forecast & Price Target

$17.77 -0.60 (-3.27%)

Closing price 02/21/2025 04:00 PM Eastern

Extended Trading

$17.95 +0.18 (+1.01%)

As of 02/21/2025 07:57 PM Eastern

Arvinas - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
0

Buy
13

Based on 13 Wall Street analysts who have issued ratings for Arvinas in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 13 have given a buy rating for ARVN.

Consensus Price Target

$60.00
237.65% Upside

According to the 13 analysts' twelve-month price targets for Arvinas, the average price target is $60.00. The highest price target for ARVN is $87.00, while the lowest price target for ARVN is $32.00. The average price target represents a forecasted upside of 237.65% from the current price of $17.77.

Get the Latest News and Ratings for ARVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arvinas and its competitors.

ARVN Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$60.00	$63.50	$61.08	$54.40
Forecasted Upside	237.65% Upside	252.78% Upside	136.21% Upside	15.74% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

ARVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arvinas Stock vs. The Competition

Type	Arvinas	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	237.65% Upside	29,211.93% Upside	14.38% Upside
News Sentiment Rating	Positive News See Recent ARVN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/12/2025	Oppenheimer 3 of 5 stars	Matthew Biegler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$40.00 ➝ $45.00	+151.26%
2/12/2025	BMO Capital Markets 4 of 5 stars	Etzer Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$88.00 ➝ $82.00	+334.34%
2/12/2025	Guggenheim 2 of 5 stars	Michael Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00	+202.72%
2/12/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Bradley Canino Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$63.00 ➝ $51.00	+188.46%
2/11/2025	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$57.00	+222.40%
2/7/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Li Watsek Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
2/3/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Peter Lawson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$48.00 ➝ $32.00	+81.71%
12/11/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$87.00 ➝ $87.00	+253.80%
12/10/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Mukherjee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$69.00	+175.12%
11/18/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00	+144.66%
Get the Latest News and Ratings for ARVN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.
5/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$63.00 ➝ $60.00	+83.43%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$65.00	+57.73%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$36.00 ➝ $55.00	+15.14%
2/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+68.67%
12/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$32.00 ➝ $40.00	+38.07%
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $20.00	+31.06%
10/23/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$70.00 ➝ $55.00	+278.01%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$81.00 ➝ $61.00	+92.01%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:39 AM ET.

ARVN Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Arvinas is $60.00, with a high forecast of $87.00 and a low forecast of $32.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARVN shares.
: According to analysts, Arvinas's stock has a predicted upside of 237.65% based on their 12-month stock forecasts.
: Arvinas has been rated by research analysts at Barclays, BMO Capital Markets, BTIG Research, Cantor Fitzgerald, Guggenheim, HC Wainwright, Oppenheimer, Stifel Nicolaus, and Wedbush in the past 90 days.
: Analysts like Arvinas more than other "medical" companies. The consensus rating for Arvinas is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARVN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ARVN) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Stock Forecast & Price Target